Theranostic Approach for Pancreatic Cancer modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property through introducing new strategies and drugs for tackling the disease. It brings information about ongoing research as well as clinical data about pancreatic cancer and provides detailed descriptions about diagnostic and therapeutic options for easy understanding. The book discusses several topics related to pancreatic cancer, such as stem cells, drug resistance and pancreatic tumor microenvironment, the latest developments in chemotherapy for metastatic cancer and chemoprevention, and epigenome as a therapeutic strategy.
Additionally, it encompasses a discussion on theranostic clinical applications for personalized treatment and management of pancreatic cancer. The book is a valuable resource for cancer researchers, oncologists, and several members of the biomedical field who need to understand more about the diagnosis and treatment of pancreatic cancer.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. Biology, pathophysiology and epidemiology of pancreatic cancer2. Diagnosis of pancreatic cancer
3. Current knowledge on drug resistance and therapeutic approaches to eliminate pancreatic cancer stem cells
4. Drug resistance and microenvironment in pancreatic cancer
5. The role of tumor microenvironment in the metastasis of pancreatic cancer and immunotherapy
6. Latest developments in chemotherapy for metastatic pancreatic cancer
7. Genetic manipulations with chemotherapy in pancreatic cancer
8. Genetic predisposition for pancreatic cancer
9. Pancreatic cancer resistance to chemotherapy: Resensitization strategies using resveratrol
10. Anti-cancer activity of a small molecule, tolfenamic acid: An emphasis on pancreatic cancer
11. Targeting the epigenome as a therapeutic strategy for pancreatic tumors Non-coding RNAs and chromatin remodelers
12. Pancreatic cancer chemoprevention: A review on molecular pathways involved in carcinogenesis and targeting with terpenoids, a new potential anti-tumor drugs
13. Meta-analysis on MTHFR polymorphisms and pancreatic cancer susceptibility
14. Therapeutic vaccines for pancreatic cancer
15. Epidermal growth factor receptor role in pancreatic cancer
16. Recent advances in molecular diagnostics and therapeutic targets for pancreatic cancer
Authors
Ganji Purnachandra Nagaraju Assistant Professor, School of Medicine, Division of Hematology and Oncology, University of Alabama, Birmingham, AL, United States.. Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju's research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books in Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR). Sarfraz Ahmad Director of Clinical Research, Gynecologic Oncology Department of AdventHealth (formerly Florida Hospital) Cancer Institute (FHCI), Orlando, FL, USA. Doctor Sarfraz Ahmad is Director of Clinical Research at the Gynecologic Oncology Department of the Advent Health (formerly Florida Hospital) Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD degree in Biochemistry from North-Eastern Hill University, Shillong. Before joining AHCI in 2002, he spent 2-years at the Indian Institute of Technology-Delhi as a researcher, and 10-years in research/teaching at the Loyola University of Chicago and the University of Illinois at Chicago's Division of Hematology/Oncology, College of Medicine. Currently, he is Professor of Medical Education at the University of Central Florida, College of Medicine and Professor of Clinical Sciences at the Florida State University College of Medicine, Orlando, USA. He has trained numerous fellows, residents, medical students, and graduate/undergraduate students during their scholarly research projects and theses.Dotor Ahmad's current research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology/hematology patients and to better understand the cellular/molecular mechanisms of cancer and related thrombo-embolic/hematologic disorders. His investigations are also aimed towards the evaluation of novel treatment options (chemo/cellular/immuno-therapies) for better management of hemato-oncologic patients. His past research interests focused on the anticoagulants, antithrombin, antiplatelet, and thrombolytic drug development for the management of hematologic and cardiovascular patients. In these various areas of biomedical research and international collaborations, Dr. Ahmad has published over 200 peer-reviewed scholarly research articles and book chapters, and nearly 400 scientific abstracts, which are extensively cited globally. He is a reviewer and has editorial responsibilities for several biomedical journals/books; he has received several competitive research grants and national/international awards for his research contributions/accomplishments. In addition to biomedical science endeavors, Dr. Ahmad is passionate about classical Hindi-Urdu literature & poetry and takes pride with active participation in such forums.
